Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management

Evelyn S. Marienberg, MD


November 08, 2022

For metastatic and advanced prostate cancer, androgen deprivation therapy (ADT) has been found to be mostly palliative with nearly all cases eventually progressing to castration-resistant prostate cancer (CRPC). CRPC is characterized as biochemical, clinical, or radiographic progression despite having castrate levels of serum testosterone. Once confirmation that serum testosterone is at castration levels, management of prostate cancer is based on a variety of factors.

How familiar are you with the management of CRPC? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.